Insights into anticancer activity and mechanism of action of a ruthenium(II) complex in human esophageal squamous carcinoma EC109 cells

A ruthenium(II) complex [Ru(p-cymene)(NHC)Cl2] (NHC=1,3-bis(4-(tert-butyl)benzylimidazol-2-ylidene), referred to as L-4, has been designed and synthesized recently in order to look for new anticancer drugs with high efficacy and low side effects. The anticancer activity and mechanism of action of L-...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European journal of pharmacology 2016-09, Vol.786, p.60-71
Hauptverfasser:	Guo, Liubin, Lv, Gaochao, Qiu, Ling, Yang, Hui, Zhang, Li, Yu, Huixin, Zou, Meifen, Lin, Jianguo
Format:	Artikel
Sprache:	eng
Schlagworte:	Anticancer activity Antineoplastic Agents - chemistry Antineoplastic Agents - pharmacology Apoptosis - drug effects bcl-2-Associated X Protein - metabolism Calcium - metabolism Carcinoma, Squamous Cell - pathology Caspase 3 - metabolism Caspase 9 - metabolism Cell Line, Tumor Cell Proliferation - drug effects Cell Survival - drug effects Cytochromes c - metabolism Down-Regulation - drug effects Ec109 Esophageal Neoplasms - pathology Esophageal Squamous Cell Carcinoma Human esophageal squamous carcinoma Humans Intracellular Space - drug effects Intracellular Space - metabolism Mechanism of action Membrane Potential, Mitochondrial - drug effects Models, Molecular Molecular Conformation Organometallic Compounds - chemistry Organometallic Compounds - pharmacology Protein Transport - drug effects Proto-Oncogene Proteins c-bcl-2 - metabolism Ruthenium - chemistry Ruthenium(II) complex
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!